Selexipag
Uptravi · ATC code B01AC27
Also known as: Seleksipag · Brand names: Uptravi, Selexipag Ratiopharm, Selexipag Beta, Selegri, Selpenza
- Key facts
- Active substance
- Selexipag
- Drug class
- Antithrombotic
- ATC code
- B01AC27
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Uptravi 100 microgram film-coated tablets / Uptravi 200 microgram film-coated tablets / Uptravi 400 microgram film-coated tablets
- Marketing authorisation holder
- Janssen Cilag International NV
- Information as of
- 2026-10-28
Key facts
Selexipag is an oral, selective prostacyclin (IP) receptor agonist. It is used for long-term treatment of pulmonary arterial hypertension (PAH) in adults.
What it is used for
- Long-term treatment of PAH in adults with WHO functional class II–III: as combination therapy when insufficiently controlled with an endothelin receptor antagonist and/or PDE-5 inhibitor, or as monotherapy in patients who are not candidates for these therapies.
Dosing
- Uptravi (film-coated tablets): starting dose 200 micrograms twice daily, approximately 12 hours apart; increase by 200 micrograms twice daily, usually at weekly intervals, to the highest individually tolerated dose (maximum 1600 micrograms twice daily).
- At the start and at each up-titration step, take the first dose in the evening; if a dose is not tolerated, reduce to the previous dose level.
- If treatment is missed for 3 days or more, restart at a lower dose; withdraw gradually while an alternative therapy is introduced.
- Moderate CYP2C8 inhibitors (e.g. clopidogrel, deferasirox, teriflunomide): halve the total daily dose.
- Moderate hepatic impairment (Child-Pugh B): starting dose 100 micrograms twice daily; severe hepatic impairment: do not use. Severe renal impairment: titrate with caution; not for patients on dialysis.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Severe coronary heart disease or unstable angina; myocardial infarction within the last 6 months; decompensated cardiac failure if not under close medical supervision; severe arrhythmias.
- Cerebrovascular events (e.g. TIA, stroke) within the last 3 months; congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension.
- Concomitant strong CYP2C8 inhibitors (e.g. gemfibrozil).
Important warnings
- Vasodilatory effects may lower blood pressure; caution with antihypertensives, resting hypotension, hypovolaemia or severe left ventricular outflow obstruction.
- Hyperthyroidism has been observed; check thyroid function if symptoms occur.
- If pulmonary oedema occurs, consider pulmonary veno-occlusive disease; discontinue if confirmed.
- Limited experience over 75 years of age – use with caution.
Side effects
- Most common: headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia and flushing – mainly during up-titration, mostly mild to moderate.
- Others: anaemia, hyperthyroidism, decreased appetite, weight decrease, sinus tachycardia.
Interactions
- Strong CYP2C8 inhibitors (e.g. gemfibrozil) are contraindicated; moderate CYP2C8 inhibitors require halving the dose.
- Pharmacokinetics not affected by warfarin; for other interactions see the full text.
Pregnancy and breastfeeding
- Women of childbearing potential should use effective contraception; not recommended during pregnancy or without contraception.
Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
This product has no separate US patient information.
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- UptraviJanssen Cilag International NV · EMEA/H/C/003774
Source: European Medicines Agency (EMA), product information
Austria
- Selexipag RatiopharmRatiopharm Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29
Germany
- Selexipag BetaBetapharm Arzneimittel Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29
Turkey
- SelegriABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 9 register entries
- SelpenzaSABA İLAÇ SAN. VE TİC. A.Ş. · 9 register entries
- UptraviJOHNSON AND JOHNSON SIHHİ MAL. SAN. VE TİC. LTD. ŞTİ. · 9 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 18 more European countries
- Croatia
- Seleksipag Accord
- Cyprus
- Selexipag Accord
- Denmark
- Selexipag Accord, Selexipag Stada
- Estonia
- Selexipag Stada
- Greece
- Xipeno
- Iceland
- Selexipag Stada, Uptravi
- Ireland
- Selexipag Accord, Selexipag Clonmel
- Italy
- Selexipag Accord, Selexipag Eg
- Latvia
- Selexipag Stada
- Liechtenstein
- Uptravi
- Lithuania
- Selexipag Stada
- Malta
- Selexipag Clonmel, Selexipag Rontis
- Netherlands
- Seleksipag Accord, Selexipag Abdi, Selexipag Accord, Selexipag Stada, Selexipag Synthon, Selexipag Teva, Xipeno
- Norway
- Selexipag Accord, Selexipag Stada, Uptravi
- Poland
- Selexipag, Selexipagum Teva
- Portugal
- Selexipag Accord, Selexipag Teva
- Spain
- Selexipag Accord, Selexipag Stada
- Sweden
- Selexipag
EMA – Article 57 product data (EU/EEA), 2026-10-29
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Related calculators
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Uptravi – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/uptravi-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC B01AC.
Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.